Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Agios Pharmaceuticals, Inc. (AGIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. As a Delaware corporation with common stock traded on the Nasdaq Global Select Market, Agios submits current and periodic reports to the U.S. Securities and Exchange Commission that document its financial condition, governance decisions, and material events.
For investors analyzing AGIO, key filings include Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s rare disease business, risk factors, research and development spending, and details on commercial-stage activities around products such as PYRUKYND (mitapivat) and AQVESME (mitapivat). Form 8-K current reports capture material developments, including quarterly financial results, stock incentive plan amendments, director elections, regulatory updates, and safety-related communications.
This page also surfaces proxy statements and exhibits referenced in filings, which can provide insight into stock incentive plans, non-employee director compensation, and shareholder voting outcomes. Where applicable, Form 4 and other ownership filings can be used to review insider transactions by directors and officers.
Stock Titan enhances these SEC documents with AI-powered summaries that explain complex sections in plain language, helping users quickly understand what each filing means for Agios’ rare disease strategy, PK activation franchise, and capital allocation. Real-time updates from EDGAR ensure that new AGIO filings appear promptly, while structured access to 10-Ks, 10-Qs, 8-Ks, and ownership reports allows for efficient due diligence on this commercial-stage biopharmaceutical company.
AGIO Pharmaceuticals reported a proposed sale of 2,940 shares of Common Stock under a Form 144 notice dated 04/02/2026, arising from the vesting of Restricted Stock Units. The filing also reports a prior sale of 4,055 shares on 03/02/2026.
The Form 144 lists the broker Morgan Stanley Smith Barney LLC and shows monetary figures adjacent to the share entries. The filing documents a routine affiliate sale notice tied to RSU vesting.
AGIO filed a Form 144 reporting the vesting of 3,280 restricted stock units on 04/02/2026. The filing also records a prior sale of 5,218 shares by James Burns on 03/02/2026, shown under "Securities Sold During The Past 3 Months."
The Vanguard Group filed Amendment No. 10 to Schedule 13G/A reporting zero beneficial ownership of Agios Pharmaceuticals Inc. common stock as of 03/13/2026. The filing explains an internal realignment effective January 12, 2026, that disaggregated beneficial ownership among Vanguard subsidiaries.
Agios Pharmaceuticals executive Krishnan Viswanadhan, Chief Corp Dev & Strategy, reported several equity transactions on March 5, 2026 tied to restricted stock units (RSUs). He exercised 8,100 RSUs, converting them into 8,100 shares of common stock at a price of $0.00 per share, reflecting the nature of RSUs as equity awards rather than open-market purchases. Following this, 2,959 common shares were sold at $27.80 per share to cover tax withholding obligations related to the RSU vesting, under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, he directly held 16,200 RSUs and 5,141 common shares. The RSUs were granted on March 5, 2025, with the underlying shares scheduled to vest in three equal annual installments beginning March 5, 2026.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 reporting a proposed resale related to the vesting of 2,959 Restricted Stock Units into Common Stock. The vesting and proposed sale date is 03/05/2026, and the shares are listed on Nasdaq.
AGIOS PHARMACEUTICALS, INC. reported that Principal Accounting Officer Theodore James Washburn Jr. completed an open-market sale of common stock. On March 3, 2026, he sold 5,272 shares at a price of $28.88 per share and held 868 shares of common stock afterward.
AGIOS PHARMACEUTICALS, INC. Chief Executive Officer Brian Goff reported multiple equity-related transactions in company stock. On March 1, 2026, he received 48,000 restricted stock units and 174,000 stock options, each RSU representing the right to receive one share of common stock, with both awards vesting over several years as described.
On March 2, 2026, previously granted restricted stock units vested and were converted into common shares through exercises of 8,500, 18,000, and 13,000 RSUs. In connection with these vestings, he sold a total of 18,055 shares of common stock at $28.96 per share to cover tax withholding obligations, under durable automatic sale instructions referenced as compliant with Rule 10b5-1(c). After these transactions, he directly held 164,548 shares of AGIOS common stock.
AGIOS PHARMACEUTICALS, INC. Chief Legal Officer James William Burns reported multiple equity transactions. On March 1, 2026, he received grants of 14,000 restricted stock units and 52,000 stock options, both vesting over several years beginning March 1, 2027. On March 2, 2026, he exercised previously granted restricted stock units into common shares and reported open-market sales totaling 5,218 common shares at $28.96 per share to cover tax withholding obligations related to performance share vesting. These sales were executed under durable automatic sale instructions consistent with Rule 10b5-1(c). Following these transactions, he directly held 44,086 common shares.
AGIOS PHARMACEUTICALS Chief Medical Officer Sarah Gheuens reported multiple equity transactions. On March 2, 2026, she exercised restricted stock units into common shares and sold a total of 4,055 common shares at $28.96 per share to cover tax withholding obligations under pre-set Rule 10b5-1 instructions. Following these transactions, she directly held 74,406 shares of common stock. On March 1, 2026, she also received equity compensation grants of 14,000 and 22,000 restricted stock units and 52,000 stock options, all vesting over multi-year schedules beginning in March 2027.
AGIOS PHARMACEUTICALS, INC. Chief Financial Officer Cecilia Jones reported a mix of equity awards, vesting and related share sales. On March 1, 2026, she received 14,000 restricted stock units and stock options for 52,000 shares, with RSUs vesting in three equal annual installments and the option vesting 25% on March 1, 2027 and the remaining 75% in 36 equal monthly installments.
On March 2, 2026, multiple restricted stock unit tranches were exercised into common stock, and a total of 5,035 common shares were sold at $28.96 per share. Footnotes state these sales were made to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c) and included in prior restricted stock unit agreements. After these transactions, she directly owned 49,328 common shares of Agios common stock.